Esophageal Cancer Surgery Cost Calculator
This calculator estimates the out-of-pocket cost of esophageal cancer treatment in Korea and keeps the same pure calculation model as the Korean page. About 90 percent of esophageal cancer in Korea is squamous cell carcinoma (C15), driven by alcohol and smoking and often located in the upper and middle esophagus, unlike the adenocarcinoma common in the West. The treatment depends on stage and location: endoscopic submucosal dissection (ESD) for early mucosal (T1a) tumors, esophagectomy with gastric-conduit reconstruction (McKeown three-field or Ivor Lewis) for invasive disease, definitive chemoradiation (CCRT) for cervical or unresectable tumors, an esophageal self-expanding metal stent (SEMS) to relieve dysphagia, chemotherapy priced per cycle, and robotic esophagectomy (RAMIE) whose robot fee is entirely out of pocket — all on 2026 Korean rules.
Treatment options by stage and location, and covered fees
Early mucosal cancer (T1a) can be removed by endoscopic submucosal dissection (ESD), which preserves the esophagus and uses about KRW 3,000,000 covered for a short admission — roughly KRW 165,000 self-pay at the 5 percent special-case rate. Invasive cancer needs esophagectomy: the model uses KRW 24,000,000 covered with a 21-day stay, plus a KRW 2,000,000 covered add-on for a cervical (McKeown three-field) anastomosis because it involves more extensive three-field lymphadenectomy.
Definitive chemoradiation (CCRT) uses about KRW 10,000,000 covered, delivered mostly as outpatient radiation over roughly six weeks. An esophageal stent (SEMS) for malignant dysphagia uses about KRW 3,000,000 covered. Robotic esophagectomy (RAMIE) charges the robot fee entirely out of pocket (KRW 8,000,000 to KRW 18,000,000, average KRW 12,000,000 before regional and hospital adjustment), while the covered surgery base is zero — so the ward fee is the only covered part.
- Neoadjuvant chemoradiation before surgery (the CROSS trimodality approach) adds KRW 8,000,000 as a covered add-on for resection surgery types.
- A cervical (McKeown three-field) anastomosis adds KRW 2,000,000 covered versus an intrathoracic (Ivor Lewis) anastomosis.
- Covered ward fee is KRW 100,000 per inpatient day; chemotherapy and CCRT are outpatient (no ward fee).
- Chemotherapy is billed per cycle and repeated; the model multiplies the per-cycle covered fee by the number of cycles.
Why neoadjuvant chemoradiation (CROSS) matters
Locally advanced but resectable esophageal cancer is usually treated with chemotherapy plus radiation before surgery (the CROSS trimodality regimen) rather than surgery alone. Shrinking the tumor first raises the complete-resection rate and suppresses micrometastases, and large trials show it improves cure and survival over surgery alone. Selecting the neoadjuvant option adds the covered chemoradiation course to the esophagectomy cost.
The typical regimen is weekly carboplatin plus paclitaxel with concurrent radiation for about five weeks, followed by esophagectomy four to eight weeks after radiation ends, with nutrition and physical recovery in between. Very early cancers skip neoadjuvant therapy, and unresectable disease uses definitive CCRT or palliative chemotherapy instead — so neoadjuvant therapy is the strategy specifically for resectable-but-advanced tumors.
Anastomosis site, leak, and dysphagia relief
The signature complication of esophagectomy is a leak where the remaining esophagus is joined to the pulled-up gastric conduit. A cervical (McKeown three-field) anastomosis is common for upper and middle tumors; a neck leak is easier to drain and manage but occurs somewhat more often, and temporary vocal-cord palsy or dysphagia can follow. An intrathoracic (Ivor Lewis) anastomosis is used for lower and gastroesophageal-junction tumors; a chest leak is rarer but can become severe (mediastinitis), so early detection matters.
For unresectable or metastatic disease, dysphagia itself is the main quality-of-life problem. An esophageal stent (SEMS) widens the blocked esophagus so the patient can eat, but the stent can occlude or migrate as the tumor grows and may need reinsertion, and chest pain or reflux can occur. The stent is covered, so special-case registration keeps the self-pay low.
Robotic surgery has limited proven advantage
Robotic esophagectomy (RAMIE) is minimally invasive, but esophageal cancer already has open and thoracoscopic (VATS) minimally invasive esophagectomy (MIE) as the standard, and RAMIE has not clearly shown a survival or complication advantage over MIE. The robot fee is entirely self-pay (about KRW 8,000,000 to KRW 18,000,000), so the calculator shows a robot-versus-covered-surgery comparison so patients can weigh the extra cost against the covered open or MIE option.
The robot fee can also face private indemnity disputes, where the insurer uses a medical review to argue the covered open or MIE surgery was medically sufficient and limits or denies payment. Keep the surgeon’s recommendation and medical-necessity documentation, and note that fifth-generation indemnity (from May 2026) reimburses non-covered items at only 50 percent.
Cancer special-case copay, indemnity, and tax credit
Ordinary inpatient treatment uses a 20 percent NHI copay. Esophageal cancer special-case registration (cancer code V193) reduces the covered copay to 5 percent for 5 years when registered within 30 days of diagnosis, but it never applies to the non-covered robotic fee, upper-grade room charges, pain-control injections, or proton and carbon-ion therapy. Inpatient days beyond day 31 may use 10 percent. This is grounded in National Health Insurance Act Article 44 and Enforcement Decree Article 19 and annex 2.
The estimate separates covered procedure fee, covered ward fee, robotic fee, room surcharge, pain-control injection, caregiver cost, private indemnity reimbursement, and the Korean medical expense tax credit (3 percent of salary threshold, 15 percent credit rate, with no KRW 7,000,000 cap for cancer patients as severe-disease patients under Income Tax Act Article 59-4). The annual copay ceiling (about KRW 870,000 to KRW 8,430,000 by income decile in 2026) can refund excess covered copay, and public health center cancer cost support (up to KRW 3,000,000 per year) may apply.
How to read the result
Enter the treatment (ESD, esophagectomy, CCRT, esophageal stent, chemotherapy, or robotic surgery), resectability, special-case registration, and — for surgery — the anastomosis site and whether neoadjuvant chemoradiation (CROSS) is given, or for chemotherapy the regimen (FP, paclitaxel plus carboplatin, or pembrolizumab plus FP) and cycle count. The result shows covered and non-covered self-pay, the chemotherapy cycle accumulation, the robot-versus-covered surgery comparison, the special-case 5 percent versus 20 percent comparison, and the final cost after private indemnity and tax credit.
This is a cost-planning estimate based on 2026 Korean rules, not medical advice. Public single-price tables for esophageal surgery do not exist, so surgery figures are defensible market-estimate ranges that vary with hospital, stage, extent of resection, approach, complications, and drugs used. Confirm details with the treating multidisciplinary team, the insurer, and the hospital quote.
This calculator is based on Korean rules (2026 National Health Insurance cancer special-case program, Income Tax Act Article 59-4 medical expense tax credit, and market cost estimates for esophageal cancer surgery, chemoradiation, and chemotherapy). Figures are planning estimates, not medical advice, an insurer decision, or a hospital quote.